Home > Inhibitors & Agonists > Membrane Transporter/Ion Channel > SGLT
Cat. No. Product name CAS No.
DC8186 Bexagliflozin(THR1442,EGT1442)| Featured

Bexagliflozin is a potent and selective SGLT2 inhibitor with IC50 value of 5.6 μM /2 nM in SGLT1 /SGLT2 respectively.

1118567-05-7
DC3111 Canagliflozin Featured

Canagliflozin is a highly potent and selective SGLT2 inhibitor for CHO-hSGLT2, CHO-rSGLT2 and CHO-mSGLT2 with IC50 of 4.4 nM, 3.7 nM and 2 nM, respectively.

842133-18-0
DC6904 DAPAGLIFLOZIN Featured

DAPAGLIFLOZIN is a SGLT-2 inhibitor.

461432-26-8
DCAPI1573 Ipragliflozin (ASP1941) Featured

Ipragliflozin (ASP1941) is a Novel Selective Sodium-Dependent Glucose Co-Transporter 2 Inhibitor, on Urinary Glucose Excretion in Healthy Subjects

761423-87-4
DC10765 LX-2761

LX2761 is a locally acting SGLT1 inhibitor that is highly potent in vitro and delays intestinal glucose absorption in vivo to improve glycemic control.

1610954-97-6
DC7921 Sotagliflozin (LX-4211) Featured

LX-4211 is a potent dual SGLT2/1 inhibitor; Antidiabetic agents.

1018899-04-1
DC3108 PF-04971729 (Ertugliflozin) Featured

PF-04971729 is a potent and selective inhibitor of the sodium-dependent glucose cotransporter 2, is currently in phase 2 trials for the treatment of diabetes mellitus.

1210344-57-2
DC7826 Tofogliflozin hydrate

Tofogliflozin is an inhibitor of subtype 2 sodium-glucose transport protein (SGLT2).

1201913-82-7
DC39092 Ipragliflozin L-Proline Featured

Ipragliflozin L-Proline is an orally active and selective inhibitor of SGLT2 with IC50 of 7.38 nM, 6.73 nM and 5.64 nM for human SGLT2, rat SGLT2 and mouse SGLT2, respectively.

951382-34-6
DC44567 Ertugliflozin L-pyroglutamic acid

Ertugliflozin (MK-8835, PF-04971729) L-pyroglutamic acid is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2) with IC50 of 0.877 nM for h-SGLT2. Ertugliflozin has the potential for the treatment of typ

1210344-83-4
DC46869 Luseogliflozin hydrate

Luseogliflozin (TS 071) hydrate is a selective potent and orally active second-generation sodium-glucose co-transporter 2 (SGLT2) inhibitor with an IC50 of 2.26 nM. Luseogliflozin hydrate can be used for the research of type 2 diabetes mellitus (T2DM).

1152425-66-5
DC46870 Enavogliflozin Featured

Enavogliflozin (DWP-16001), an antidiabetic agent, is an orally active, best-in-class and selective sodium-glucose cotransporter-2 (SGLT-2) inhibitor.

1415472-28-4
DC48201 SGLT1/2-IN-2

SGLT1/2-IN-2 demonstrates potent dual inhibitory activities (IC50 = 96 nM for SGLT1 and IC50 = 1.3 nM for SGLT2).

2387812-73-7
DC72657 Velagliflozin proline hydrate

Velagliflozin proline hydrate is the clinical form of Velagliflozin. Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations.

1661838-94-3
DC72658 Velagliflozin (proline)

Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations.

1539295-26-5
DC72659 Sergliflozin etabonate

Sergliflozin etabonate (GW-869682X) is a potent and orally active sodium glucose cotransporter (SGLT2) inhibitor. Sergliflozin etabonate shows antidiabetic and antihyperglycemic effects. Sergliflozin etabonate significantly reduces non-fasting blood glucose levels in diabetic mice. Sergliflozin etabonate has the potential for the research of diabetes.

408504-26-7
DC72660 Henagliflozin

Henagliflozin (SHR3824) is a potent selective sodium-glucose co-transporter 2 (SGLT2) inhibitor with the IC50 values of 2.38 and 4324 nM for human SGLT2 and SGLT1, respectively. Henagliflozin can be used in diabetes research.

1623804-44-3
Page 1 / Total 1 FirstPrevNextLastGoto